Keywords: elastin; Hsp90; MMP-2; uPA; invasion

Elastin peptides regulate HT-1080 fibrosarcoma cell migration and invasion through an Hsp90-dependent mechanism

M Donet^{1,2}, S Brassart-Pasco^{1,2}, S Salesse^{1,2}, F-X Maquart^{1,2,3} and B Brassart^{*,1,2}

¹Laboratoire de Biochimie Médicale et Biologie Moléculaire, UMR CNRS/URCA 7369 MEDyC, UFR Médecine, Université de Reims Champagne Ardenne, 51 Rue Cognacq Jay, 51095 Reims, France; ²CNRS UMR 7369, Matrice Extracellulaire et Dynamique Cellulaire – MEDyC, 51 Rue Cognacq Jay, 51095 Reims, France and ³CHU de Reims, Laboratoire Central de Biochimie, 51092 Reims, France

Background: The elastin-derived peptides (EDPs) exert protumoural activities by potentiating the secretion of matrix metalloproteinases (MMP) and the plasminogen–plasmin activating system. In the present paper, we studied heat-shock protein 90 (Hsp90) involvement in this mechanism.

Methods: HT-1080 fibrosarcoma cell migration and invasion were studied in artificial wound assay and modified Boyden chamber assay, respectively. Heat-shock protein 90 was studied by western blot and immunofluorescence. Matrix metalloproteinase–2 and urokinase plasminogen activator (uPA) were studied by gelatin ± plasminogen zymography and immunofluorescence. Heat-shock protein 90 partners were studied by immunoprecipitation. Messenger RNA expression was studied using real-time PCR. Small interfering RNAs were used to confirm the essential role of Hsp90.

Results: We showed that kappa-elastin and VGVAPG elastin hexapeptide stimulated Hsp90, pro-MMP-2 and uPA secretion within 6 h, whereas AGVPGLGVG and GRKRK peptides had no effect. No increase of mRNA level was observed. Heat-shock protein 90-specific inhibitors inhibit EDP-stimulated HT-1080 cell-invasive capacity and restrained EDP-stimulated pro-MMP-2 and uPA secretions. The inhibitory effect was reproduced by using Hsp90-blocking antibody or Hsp90 knockdown by siRNA. Heat-shock protein 90 interacted with and stabilised uPA and pro-MMP-2 in conditioned culture media of HT-1080 fibrosarcoma cells.

Conclusions: Taken together, our results demonstrate that EDPs exert protumoural activities through an Hsp90-dependent mechanism involving pro-MMP-2 and uPA.

Tumour invasion involves many interactions between tumour cells and extracellular matrix (ECM). It is mediated through specific events including receptor-mediated recognition, attachment and ECM degradation, leading to the migration of cells towards a chemotactic agent (Starkey, 1990).

Elastin has a key role in matrix biology. It is the major component of elastic fibres, particularly abundant in tissues such as arteries and lung, and also present in skin, breast, cartilage and some ligaments. It is a long-lived macromolecule with no detectable turnover (Rucker and Dubick, 1984). Its proteolysis by elastase-type proteinases (metallo, serine and cysteine families) is

linked to the genesis of several diseases affecting elastin-rich organs (Werb *et al*, 1982; Visse and Nagase, 2003). This degradation is known to unmask cryptic sites within the ECM and to release matrikines, termed elastin-derived peptides (EDPs or elastokines). These EDPs display a wide range of biological activities, influencing cell migration (Senior *et al*, 1980; Hinek *et al*, 1992), differentiation (Grant *et al*, 1989), proliferation, chemotaxis (Kamoun *et al*, 1995; Maeda *et al*, 2007), survival, tumour progression (Timar *et al*, 1991; Huet *et al*, 2002; Ntayi *et al*, 2004), angiogenesis (Robinet *et al*, 2005), aneurysm formation and atherogenesis (Robert, 1996; Nackman *et al*, 1997; Hance *et al*, 2002).

*Correspondence: Dr B Brassart; E-mail: bertrand.brassart@univ-reims.fr

Received 12 March 2014; revised 4 April 2014; accepted 10 April 2014; published online 29 May 2014

© 2014 Cancer Research UK. All rights reserved 0007–0920/14

With regard to tumour invasion, soluble peptides obtained from alkaline (κ -elastin) or elastase hydrolysis of insoluble elastin, as well as tropoelastin, were shown to increase MMP-1, MMP-2 and MMP-3 production by human skin fibroblasts (Brassart *et al*, 2001; Huet *et al*, 2001). Similarly, EDPs stimulated MMP-2, MT1-MMP and TIMP-2 secretion in human HT-1080 fibrosarcoma cell line and, as a consequence, could promote the invasive and metastatic properties of tumour cells (Brassart *et al*, 1998; Huet *et al*, 2002). Cell responses to EDPs were attributed to the binding of a VGVAPG hexapeptide sequence, repeated several times in tropoelastin, to elastin receptors with lectin-like properties, named the elastin receptor complex (S-Gal/neuraminidase/ cathepsin A protective protein) or galectin-3. Nevertheless, two other elastin receptors have recently been described (Maeda *et al*, 2007; Bax *et al*, 2009). The first one, unaffected by lactose and heparin sulphate, was identified as integrin $\alpha V\beta 3$. It is involved in the divalent cation-dependent adhesion of human dermal fibroblast to the C-terminal GRKRK motif of tropoelastin. The second one, a lactose-insensitive receptor unknown to date, binds elastin-derived nonapeptides (AGVPGLGVG and AGVPGFAG) and modulates macrophage migration (Maeda *et al*, 2007) and lung cancer cells MMP-2 and urokinase plasminogen activator (uPA) secretion (Toupance *et al*, 2012).

As shown in our previous studies, EDPs increase the secretion of MMP-2 and uPA by HT-1080 cells and induce or potentiate MMP activation cascades in the presence of plasminogen (Huet *et al*, 2002). Accumulating evidences indicate that Hsp90 has important roles in both physiological and pathological processes, especially in tumour progression (Tsutsumi and Neckers, 2007). Heat-shock protein 90 is a highly conserved and abundant protein, constituting about 1% of the total intracellular protein (Grenert *et al*, 1999). In the cytosol, two isoforms of Hsp90 are referred to as Hsp90 α and Hsp90 β (Chen *et al*, 2005). Intriguingly, the Hsp90 α isoform also exists extracellularly (Tsutsumi and Neckers, 2007). Heat-shock protein 90 is secreted by neuron cells, dermal fibroblasts, keratinocytes, macrophages and epithelial cells. It participates in neuronal cell migration, wound healing and viral and bacteria infection. Heat-shock protein 90 can be detected in the blood of cancer patients, and the level of Hsp90 α is positively associated with tumour malignancy (Wang *et al*, 2009). Eustace *et al* (2004) reported that extracellular Hsp90 α can interact with MMP-2 and that immobilised geldanamycin, an impermeable inhibitor of Hsp90 α , inhibits MMP-2 proteolytic activity. More recently, Song *et al* (2010) and Sims *et al* (2011) demonstrated that extracellular Hsp90 modulates the MMP-2-dependent tumour processes by enhancing MMP-2 activation, stabilising and preventing MMP-2 inactivation processing.

In the present study, our aim was to determine if EDPs were also able to increase the extracellular presence of Hsp90 and to induce MMP-2 and uPA accumulation in the cell culture medium through the formation of an extracellular Hsp90/MMP-2/uPA complex. We demonstrate that the presence of kappa-elastin (Kel) and VGVAPG stimulates Hsp90 secretion. Heat-shock protein 90 upregulation followed by EDP treatment generated MMP-2 and uPA accumulation, thereby strongly potentiating cancer cell migration and matrix invasion capacities.

MATERIALS AND METHODS

Reagents. Synthetic elastin peptides (VGVAPG, AGVPGLGVG and GRKRK) were purchased from Proteogenix (Schiltigheim, France). Matrigel was obtained from Becton-Dickinson (Le Pont de Claix, France). Plasminogen, mouse anti-MMP-2 and anti-uPA antibodies were obtained from Calbiochem (distributed by VWR, Strasbourg, France). Geldanamycin was obtained from Invivogen (Toulouse, France). Radicol was purchased from Tebu-bio

(Le Perray-en-Yvelines, France). Rabbit monoclonal anti-Hsp90 was from Ozyme (Saint Quentin Yvelines, France). Mouse anti-Hsp90 was purchased from Abcam (Paris, France). Goat anti-actin was from Santa Cruz (Heidelberg, Germany). Recombinant Hsp90 α protein was from Enzo Life Sciences (Villeurbanne, France).

Materials. Insoluble elastin was prepared from bovine ligamentum nuchae by hot alkali treatment and its purity was assessed by amino-acid analysis and lack of hexoses and hexosamines in the preparation (Jacob and Hornebeck, 1985). Soluble Kel peptides were obtained from purified insoluble elastin by organoalkaline hydrolysis (Samouillan *et al*, 2001). Peptides with an average molecular weight of 75 kDa were isolated by gel permeation on Sephadex G100 (Sigma-Aldrich, Saint Quentin Fallavier, France).

Cell culture. Human fibrosarcoma cells (HT-1080) and breast carcinoma cells (MDA-MB-231) were obtained from the American Type Culture Collection (Rockville, MD, USA). They were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco-BRL, Fisher Scientific, Illkirch, France) supplemented with 10% fetal calf serum.

Preparation of conditioned media. Cells were grown to subconfluency in 24-well culture plates (Nunc, represented in France by Polylabo, Strasbourg) in 10% serum-containing medium. After 16 h in serum-free medium, soluble substrates, that is, Kel (from 1 to 100 $\mu\text{g ml}^{-1}$) or elastin synthetic peptides (200 $\mu\text{g ml}^{-1}$), were added to serum-free culture medium, and HT-1080 cells were incubated for 6–48 h, in the presence or absence of 1.5 μM geldanamycin, 10 μM radicol, 0.1–10 $\mu\text{g ml}^{-1}$ mouse anti-Hsp90 antibody and 1–50 $\mu\text{g ml}^{-1}$ recombinant Hsp90 α . Conditioned media were harvested and centrifuged at 10 000 g for 10 min at room temperature to remove cellular debris. They were used for the determination of Hsp90, MMP-2 and uPA secretion.

Gelatin zymography. Conditioned media from HT-1080 cell cultures were analysed for gelatin degradation by electrophoresis under non-reducing conditions on an SDS-polyacrylamide gel containing 1 mg ml $^{-1}$ gelatin. The volume of conditioned medium loaded per lane was standardised on the basis of the cell count at harvest. Gels were incubated overnight at room temperature in 50 mM Tris-HCl, 150 mM NaCl and 10 mM CaCl $_2$ (pH 7.4). White lysis zones, indicative of degrading activity, were revealed by staining with Coomassie brilliant blue.

Gelatin plasminogen zymography. For the determination of plasminogen activators, conditioned media were analysed on SDS-polyacrylamide gels containing 1 mg ml $^{-1}$ gelatin and 3 $\mu\text{g ml}^{-1}$ plasminogen. Following electrophoresis, gels were incubated overnight at room temperature in 100 mM glycine buffer and EDTA 5 mM (pH 8.3). Gelatinolytic activity resulting from plasminogen activation was indicated here by white lysis zones, which were revealed by staining with Coomassie brilliant blue. As a positive control, recombinant urokinase was used; as a negative control, 2 mM phenylmethylsulphonylfluoride was added to the incubation buffer.

Western blot analysis. Conditioned media were concentrated in Vivaspin from Sartorius stedim (Aubagne, France) and samples were electrophoresed in a 0.1% SDS and 10% polyacrylamide gel, under reducing conditions. Proteins were then transferred onto Immobilon-P membrane (Millipore, Saint-Quentin en Yvelines, France). The membrane was blocked with 5% non-fat dry milk, 0.1% Tween-20 in a 50 mM Tris-HCl buffer and 150 mM NaCl (pH 7.5) (TBS) for 2 h at room temperature, incubated overnight at +4 °C with anti-Hsp90, anti-MMP-2 or anti-uPA antibody and then for 1 h at room temperature with a second peroxidase-conjugated anti-IgG antibody. Immune complexes were visualised with the ECL Chemoluminescence Detection Kit (GE Healthcare, Orsay, France).

Hsp90, pro-MMP-2 and uPA detection by immunocytofluorescence. HT-1080 cells were plated on glass slides and incubated in 10% serum-containing medium. After 16 h in serum-containing medium, $50 \mu\text{g ml}^{-1}$ Kel were added to serum-free culture medium, and HT-1080 cells were incubated for 30 min. They were fixed for 5 min with 4% paraformaldehyde. The slides were washed with PBS-T and saturated in PBS-T with 5% BSA. Cells were then incubated for 1 h at room temperature with an anti-HSP90, anti-MMP-2 and anti-uPA antibody diluted 1/400 in PBS-T with 1% BSA. Slides were washed in PBS-T and cells were incubated for 30 min with the Alexa-488- or Alexa-568-conjugated secondary antibodies diluted 1/1000 in TBS-T with 1% BSA. Cells were then washed with PBS-T. Control preparations were incubated with

omission of the first antibody. Immunofluorescence-labelled cell preparations were studied using a Zeiss LSM 710 confocal laser scanning microscope with the $\times 60$ oil-immersion objective (Carl Zeiss Microimaging, Heidelberg, Germany).

Primer design for RT-qPCR. Real-time quantitative polymerase chain reaction (RT-qPCR) primers were designed according to sequences of Hsp90 α transcript-1 (*Hsp90AA1-001*) and Hsp90 α transcript-2 (*Hsp90AA1-002*) (NM_001017963), MMP-2 (NM_004530), uPA (NM_001145031) and EEFa1 (NM_001402). The forward primer for Hsp90 α transcript-1 was 5'-GCCTTCAGACAGAGCCAAGGT-3' and the reverse primer was 5'-TCTTG GGTCTGGGTTTCTCTCA-3' with a 101 bp product. The forward

Figure 1. EDPs influence on Hsp90, pro-MMP-2 and uPA secretion. (A) Gelatin zymography, gelatin plasminogen zymography and western blotting analysis of conditioned media and actin content in total cell extracts from HT-1080 cells cultured for 6, 24 and 48 h in the absence (–) or presence of $50 \mu\text{g ml}^{-1}$ Kel (+) as described in Materials and Methods section. (B) Quantitative evaluation of pro-MMP-2 secretion by HT-1080 cells on gelatin zymography. Results (mean $\pm$ s.e.m.) were expressed as the percentage of control 6 h (EDP-untreated cells). * $P < 0.005$, ** $P < 0.001$, significantly different from control. Lighter bars, untreated cells; black bars, EDP-treated cells. (C) Quantitative evaluation of uPA secretion by HT-1080 cells on gelatin plasminogen zymography. Results (mean $\pm$ s.e.m.) were expressed as the percentage of control for 6 h (EDP-untreated cells). * $P < 0.005$, ** $P < 0.001$, significantly different from control. Lighter bars, untreated cells; black bars, EDP-treated cells. (D) Quantitative evaluation of Hsp90 secretion by HT-1080 cells by western blotting. Results (mean $\pm$ s.e.m.) were expressed as the percentage of control for 6 h (EDP-untreated cells). ** $P < 0.001$, significantly different from control. Lighter bars, untreated cells; black bars, EDP-treated cells. (E) Dose-effect study of EDP treatment (Kel 0– $100 \mu\text{g ml}^{-1}$) on pro-MMP-2, uPA and Hsp90 secretion. Gelatin zymography, gelatin plasminogen zymography and western blotting analysis of conditioned media and actin content in cell extracts from HT-1080 cells cultured for 24 h in the absence (Ctl) or in the presence of 1– $100 \mu\text{g ml}^{-1}$ Kel. (F) Gelatin zymography, gelatin plasminogen zymography and western blotting analysis of conditioned media from HT-1080 cells cultured for 24 h in the absence (Ctl) or in the presence of $50 \mu\text{g ml}^{-1}$ Kel (Kel) or synthetic elastin peptides (VGAPG, AGVPGLGVG, GRKRK). All synthetic peptides were used at $200 \mu\text{g ml}^{-1}$. Quantitative evaluation of protein secretions by HT-1080 cells on gelatin zymography, gelatin plasminogen zymography and by western blotting. Results (mean $\pm$ s.e.m.) were expressed as the percentage of control (EDP-untreated cells).

primer for Hsp90 α transcript-2 was 5'-CGTCAGTTGCTTCA GCGTCC-3' and the reverse primer was 5'-TCAACTGGGCA ATTTCTGCCT-3' with a 151 bp product. The forward primer for MMP-2 was 5'-TCTTCCCCTTCACTTTCCTG-3' and the reverse primer was 5'-ACTTGCGGTCGTCATCGTA-3' with a 111 bp product. The forward primer for uPA was 5'-CCCAGTTTGGCAC AAGCTGT-3' and the reverse primer was 5'-CCCTGGCAGG AATCTGTTTTTC-3' with a 202 bp product. The forward primer for EEf1a1 was 5'-CTGGAGCCAAGTGCTAACATGCC-3' and the reverse primer was 5'-CCGGGTTTGAGAACACCAGTC-3' with a 221 bp product. All primers were synthesised by Eurogentec (Maine Et Loire, France).

RT-qPCR. Total RNA isolation was performed using the Qiagen RNeasy Kit (Qiagen, Courtaboeuf, France) according to the manufacturer's instructions. Complementary DNA was prepared from 200 ng of total RNA by reverse transcription (RT) using a Maxima First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Villebon-sur-Yvette, France) according to the manufacturer's protocol. Real-time PCR was performed using a Maxima SYBR GREEN/ROX qPCR Master Mix (Thermo Fisher Scientific) on the Stratagene Mx3005P qPCR detection system (Agilent Technologies, Les Ulis, France). Polymerase chain reaction

conditions were 15 min at +95 °C, followed by 40 cycles each consisting of 15 s at +95 °C (denaturation) and 30 s at +60 °C (annealing/extension). Polymerase chain reaction efficiency of the primer sets (Hsp90 α transcript-1, Hsp90 α transcript-2, MMP-2, uPA and EEf1a1) was controlled via the slope of a standard curve. Results were standardised to the EEf1a1 gene expression level. Relative gene expression was determined with the formula fold induction = $2^{-\Delta\Delta Ct}$, where $\Delta\Delta Ct = (Ct_{GI} \text{ (unknown sample)} - Ct_{GI} \text{ (reference sample)}) - (Ct_{GR} \text{ (unknown sample)} - Ct_{GR} \text{ (reference sample)})$. GI represents the Gene of Interest and GR the Reference Gene. The entire experiment from RNA extraction to real-time PCR steps was repeated four times with different sets of samples.

siRNA transfection. Small interfering RNA specific to human Hsp90 α (FlexiTube GeneSolution GS3320 for HSP90AA1) and negative control siRNA (non-targeting pool), which do not target any genes, were purchased from Qiagen. The siRNA target different regions of the Hsp90 α mRNA: 1st siRNA target sequence (5'-AACCCTGACCATTCCATTATT-3'), 2nd siRNA target sequence (5'-TGCACTGTAAGACGTATGTAA-3'), 3rd siRNA target sequence (5'-CAGAATGAAGGAGAACCAGAA-3') and 4th siRNA target sequence (5'-ATGGCATGACAACACTACTTTAA-3').

Figure 2. Evaluation of the intracellular Hsp90, MMP-2 and uPA expression in HT-1080 cells. (A) Western blotting analysis of intracellular Hsp90 using a rabbit anti-Hsp90 monoclonal antibody and probing with anti-actin antibody were carried out as described in Materials and Methods section. (B) Western blotting analysis of intracellular Hsp90 at 24 h using a rabbit anti-Hsp90 monoclonal antibody and probing with anti-actin. (C–F) Localisation of Hsp90, pro-MMP-2 and uPA in HT-1080 cells in the presence (D, F) (Kel 50 $\mu\text{g ml}^{-1}$) or absence (C, E) (control) of EDPs. Cells were cultured on glass slides, fixed with paraformaldehyde and labelled with an anti-Hsp90 (green), anti-pro-MMP-2 form (red) (C, D), anti-uPA (red) (E, F). Yellow staining corresponds to areas where Hsp90, pro-MMP-2 or uPA colocalised. Scale bar: 10 μm .

Exponentially growing HT-1080 cells were transfected with two siRNA pools (siRNA1: 1st and 2nd siRNA target sequences/siRNA2: 3rd and 4th siRNA target sequences) (20 nM) (Qiagen) using Lipofectamine 2000 (Life Technologies, Fisher Scientific). Decrease of Hsp90 α mRNA expression was assessed by RT-qPCR at 48 h after transfection. Decrease of Hsp90 protein expression was monitored by western blotting and immunocytofluorescence 72 h after siRNA transfection. Cells were subjected to EDP treatment for pro-MMP-2 and uPA secretion 48 h after transfection.

Artificial wound assay. HT-1080 cells were seeded on uncoated 12-well plates in 10% serum-containing medium. A homogeneous wound was created in each well by scraping cells with a tip followed by two washes with DMEM to eliminate dead cells and cellular debris. Soluble substrates, that is, Kel (50 $\mu\text{g ml}^{-1}$), were added to serum-free culture medium and HT-1080 cells were incubated for 24 h, in the presence or absence of 1.5 μM geldanamycin or 10 μM radicicol. Wound closure was evaluated by videomicroscopy (Axiovert 200 M; Zeiss).

In vitro invasion assay. Invasion was assessed in modified Boyden chambers (tissue culture-treated, 6.5-mm diameter, 8- μm pore, Transwell; Dutscher, Brumath, France) as described previously (Huet *et al.*, 2002). Briefly, DMEM supplemented with 10% fetal bovine serum and 2% BSA was used as a chemoattractant. In total, 5×10^4 cells were suspended in serum-free DMEM containing 0.2% BSA and seeded onto membranes coated with Matrigel (50 $\mu\text{g cm}^{-2}$). After a 6 h incubation period, cells were fixed with methanol and stained with crystal violet for 15 min. Cells remaining on the upper face of the membranes were scraped, and those on the lower face were counted using an inverted microscope. Experiments

were reproduced three times in triplicates. Differences in cell invasiveness were evaluated by Student's *t*-test.

Statistical analysis. Each experiment was performed at least three times from separate sets of culture and data were expressed as mean $\pm$ s.e.m. Comparisons were performed using Student's *t*-test.

RESULTS

Influence of EDPs on Hsp90, pro-MMP-2 and uPA secretion by HT-1080. We previously demonstrated that EDPs upregulate invasiveness of tumour cells via the release of proteolytic enzymes. The mechanism leading to MMP-2- and uPA-increased release is unclear. We have not yet determined if this upregulation results from posttranscriptional mechanisms or increased enzyme stability. Heat-shock protein 90 is required for the activation and stabilisation of a wide variety of client proteins including MMP-2 and uPA, involved in promoting tumour invasiveness. Thus, we decided to study Hsp90 expression by HT-1080 after EDP stimulation. Serum-free culture media supplementation with EDPs (Kel 50 $\mu\text{g ml}^{-1}$) for 6–48 h did not induce HT-1080 cell growth. Those peptides have no cell toxicity as assessed by trypan blue exclusion (data not shown) and did not modify the overall protein content visualised by actin level in total cell extract from 6 to 48 h of culture (Figure 1A). Elastin-derived peptides stimulated pro-MMP-2 secretion by 4.5-, 2.5- and 2.1-fold at 6 h, 24 h and 48 h, respectively, as shown by zymography analysis (Figure 1B). Gelatin plasminogen zymography analysis revealed an increase in uPA secretion after EDP treatment by 2.3-, 2.0- and 1.4-fold at 6 h, 24 h and 48 h, respectively (Figure 1C). Heat-shock protein 90 secretion was also increased as soon as 6 h following supplementation of the

Figure 3. Hsp90 regulates migration and invasion of EDP-treated HT-1080 cells. **(A)** Geldanamycin and radicicol, two Hsp90 inhibitors, block the Matrigel invasion of EDP-stimulated HT-1080 cells. HT-1080 cells were incubated with 1.5 μM geldanamycin or 10 μM radicicol during 1 h before being stimulated or not for 6 h with 50 $\mu\text{g ml}^{-1}$ EDPs. At the end of the incubation period, cells were fixed with methanol and stained with crystal violet for 15 min. Cells remaining on the upper face of the membranes were scraped and those on the lower face were counted. Data are expressed as mean $\pm$ S.E.M. values from three independent experiments, each performed in triplicate. $^{**}P < 0.001$, significantly different from Kel alone). Lighter bars, untreated cells; black bars, EDP-treated cells. **(B)** Heat-shock protein 90 inhibitors (geldanamycin and radicicol) inhibit the EDP-stimulated migration of HT-1080 cells. HT-1080 cells have been seeded in 12-well plates and a homogeneous wound was created in each well by scraping cells with a tip. Cells were incubated with 1.5 μM geldanamycin or 10 μM radicicol during 1 h before being stimulated or not for 24 h with 50 $\mu\text{g ml}^{-1}$ EDPs and cell migration was evaluated by microscopy. **(C)** Quantification of the wound closure. $^{**}P < 0.001$, significantly different from Kel alone.

culture medium with $50 \mu\text{g ml}^{-1}$ of Kel. The maximum level of Hsp90 production (4.5-fold increase) by HT-1080 cells was found in the presence of $50 \mu\text{g ml}^{-1}$ of Kel after 48 h of incubation (Figure 1D). As shown in Figure 1E, zymography and western blotting analysis of EDP-treated HT-1080 cell media indicated that Kel-mediated effect on the pro-MMP-2, uPA and Hsp90 secretion was concentration-dependent; a significant 2.4-fold increase in Hsp90 secretion was observed following supplementation of the culture medium with $25 \mu\text{g ml}^{-1}$ of Kel and a 3.2-fold maximum increase of Hsp90 secretion by HT-1080 cells was found in the presence of $50 \mu\text{g ml}^{-1}$ Kel. The increase of Hsp90, MMP-2 and uPA was also observed in the conditioned media of MDA-MB-231 breast carcinoma cells treated with EDP ($50 \mu\text{g ml}^{-1}$) for 24 h (Supplementary Figure 1).

Next, we examined whether other elastin peptides (VGVPAG, AGVPGLGVG and GRKRRK) could also modulate Hsp90 production by HT-1080 cells, parallel to pro-MMP-2 and uPA secretion. While AGVPGLGVG and GRKRRK peptides had no impact, HT-1080 cells grown in the presence of $200 \mu\text{g ml}^{-1}$ VGVPAG for 24 h secreted significantly more pro-MMP-2 (1.8-fold), uPA (1.5-fold) and Hsp90 (1.9-fold) (Figure 1E) compared with control. Thus, EDPs stimulate proteases and Hsp90 secretion in a time- and concentration-dependent manner, and VGVPAG reproduced, at least partly, the EDP stimulation.

EDPs induce Hsp90, pro-MMP-2 and uPA synthesis by a posttranscriptional mechanism. Total RNAs obtained from HT-1080 cells cultured at different time points (0, 5, 15, 30, 60, 120 min

Figure 4. EDP increases extracellular Hsp90 and promotes pro-MMP-2 and uPA accumulation in HT-1080 culture media. (A) Gelatin zymography and gelatin plasminogen zymography analysis of Hsp90 inhibitors effect ($1.5 \mu\text{M}$ geldanamycin and $10 \mu\text{M}$ radicicol) on the production of pro-MMP-2 and uPA in the presence (+; $50 \mu\text{g ml}^{-1}$) or in the absence (–) of EDPs (24 h of treatment). (B) Quantitative evaluation of protein secretions by HT-1080 cells on gelatin zymography and gelatin plasminogen zymography. Results (mean $\pm$ s.e.m.) were expressed as the percentage of control (EDP-untreated cells). * $P < 0.005$, ** $P < 0.001$, significantly different from Kel alone. (C) Gelatin zymography and gelatin plasminogen zymography analysis of monoclonal anti-Hsp90 antibody effect on the production of pro-MMP-2 and uPA in EDP-treated HT-1080 cells ($50 \mu\text{g ml}^{-1}$) (24 h of treatment). (D) Quantitative evaluation of protein secretions by HT-1080 cells on gelatin zymography and gelatin plasminogen zymography. Results (mean $\pm$ s.e.m.) were expressed as the percentage of control (EDP-untreated cells). * $P < 0.005$, ** $P < 0.001$, significantly different from Kel alone. (E) Gelatin zymography and gelatin plasminogen zymography analysis of the effect of recombinant Hsp90 α protein on the production of pro-MMP-2 and uPA by HT-1080 cells (24 h of treatment). (F) Quantitative evaluation of protein secretions by HT-1080 cells on gelatin zymography and gelatin plasminogen zymography. Results (mean $\pm$ s.e.m.) were expressed as the percentage of control (EDP-untreated cells). * $P < 0.005$, ** $P < 0.001$, significantly different from control.

and 24 h) in the absence or presence of Kel ($50 \mu\text{g ml}^{-1}$) were analysed by real-time PCR. Kappa-elastin treatment induced only minor alteration of Hsp90 transcripts 1 and 2, MMP-2 and uPA mRNA levels from 5 to 120 min (Supplementary Figure 2A–C) and no statistical variation at 24 h either (Supplementary Figure 2D). These results suggest that Hsp90 increased secretion, and proteases release after EDP treatment may not implicate regulation at the transcriptional level. On the contrary, as previously reported for the MMP-2 and uPA expression (Toupance *et al*, 2012), the presence of EDPs rapidly enhanced Hsp90 protein synthesis; Kel ($50 \mu\text{g ml}^{-1}$) triggered a 4-fold induction of intracellular Hsp90 production after a 15 min incubation period and a maximal 4.5-fold induction after 30 min (Figure 2A) compared with control. Twenty-four-h Kel treatment maintained a 1.6-fold upregulated intracellular Hsp90 level (Figure 2B). Immunocytofluorescence study of Hsp90, pro-MMP-2 and uPA production by Kel-treated HT-1080 cells confirmed the upregulation of Hsp90, pro-MMP-2 and uPA synthesis (Figure 2C–F). A perinuclear colocalisation was highlighted for Hsp90 and pro-MMP-2, as well as for Hsp90 and uPA. These results demonstrate that EDPs induce Hsp90, pro-MMP-2 and uPA synthesis by a posttranscriptional mechanism.

Influence of EDP-dependent Hsp90 expression on the migratory and invasive properties of HT-1080 cells. Under our experimental conditions (Huet *et al*, 2002), untreated HT-1080 cells had a low ability to migrate and penetrate a Matrigel matrix, contrasting with the high capacity of those cells to migrate and invade in the presence of $50 \mu\text{g ml}^{-1}$ Kel (Figure 3A–C). When untreated HT-1080 cells were incubated with either Hsp90 inhibitor geldanamycin ($1.5 \mu\text{M}$) or radicicol ($10 \mu\text{M}$), no change was detected in the migratory and invasive cell capacities *vs* control cells. Adding Kel ($50 \mu\text{g ml}^{-1}$) after geldanamycin or radicicol preincubation significantly reduced the wound closure by 6.5- and 4.6-fold, respectively (Figure 3B and C), and inhibited the cell invasion of Matrigel by 3.7- and 3.6-fold, respectively, as compared with cells treated with Kel alone (Figure 3A). Taken together, these results demonstrate that Hsp90 regulates EDP-stimulating effect on HT-1080 cells migratory and invasive capacities of HT-1080 cells.

Influence of Hsp90 on pro-MMP-2 and uPA expression by HT-1080 cells. To determine if Hsp90 influences pro-MMP-2 and uPA expression, we performed zymography analysis on cell media pretreated with geldanamycin ($1.5 \mu\text{M}$) or radicicol ($10 \mu\text{M}$) and in the presence or absence of EDPs ($50 \mu\text{g ml}^{-1}$) (Figure 4A). For the cells incubated either with geldanamycin or radicicol alone, pro-MMP-2 expression was unaffected, while uPA expression was reduced. In cells treated with Kel, geldanamycin and radicicol significantly inhibited pro-MMP-2 (1.7- and 1.3-fold, respectively) and uPA synthesis (3.4- and 1.5-fold, respectively). We further investigated whether supplementation of culture media with Hsp90-blocking antibodies (0.1 – $10 \mu\text{g ml}^{-1}$) could disrupt the EDP-dependent pro-MMP-2 and uPA expression. We observed that pro-MMP-2 and uPA levels in cell medium decreased with Hsp90 antibody in a concentration-dependent manner (Figure 4B). Although the Hsp90 antibody moderately blocked the uPA production (-35%), $10 \mu\text{g ml}^{-1}$ of Hsp90 antibody induced a marked decrease of pro-MMP-2 secretion (3.3-fold decrease).

To explore the role of Hsp90 α on pro-MMP-2 and uPA, we evaluated the impact of recombinant Hsp90 α (rHsp90 α) (1 – $50 \mu\text{g ml}^{-1}$) on HT-1080 cells. As compared with EDP-treated cells, rHsp90 α effect was concentration-dependent; significant and maximum increase of pro-MMP-2 and uPA was observed following supplementation of culture media with $50 \mu\text{g ml}^{-1}$ of rHsp90 α (2.0- and 2.9-fold respectively) (Figure 4C). Collectively, these results strongly support the idea that EDPs increase expression and secretion of Hsp90 α , which, as an extracellular

chaperone protein, may protect pro-MMP-2 and uPA from degradation and increase their content in the conditioned media.

Extracellular Hsp90 interacts with MMP-2 and uPA. Our data show that EDPs enhance the expression of Hsp90, pro-MMP-2 and uPA. These three proteins are intracellularly colocalised. By affecting Hsp90 amount in the conditioned media, pro-MMP-2 and uPA were also affected. We thus studied if Hsp90 was able to interact with MMP-2 and uPA in the conditioned medium. After 24 h incubation with Kel ($50 \mu\text{g ml}^{-1}$), secreted Hsp90 was immunoprecipitated and Hsp90 client proteins were revealed by western blotting. As shown in Figure 5, we found that extracellular Hsp90 interacts with uPA and pro-MMP-2, and also with the MMP-2 active form. No enzymes were detected in the output, suggesting a complete interaction between those three extracellular proteins.

Hsp90 is essential for EDP-dependent pro-MMP-2 and uPA secretion. To confirm the essential role of Hsp90 in EDP-dependent pro-MMP-2 and uPA release, we transfected HT-1080 cells with two pools of Hsp90 siRNA (siRNA1 and siRNA2) or negative control siRNA (–) as described in Materials and Methods section. A strong decrease of Hsp90 mRNA expression (-88% and -86% for siRNA1 and siRNA2, respectively, compared with control) was observed 48 h after siRNA cell transfection (Figure 6A). To validate the Hsp90 knockdown, its protein expression pattern was analysed 72 h after transfection by western blotting. In siRNA1 and siRNA2 cells, 80% and 77% inhibition of Hsp90 protein expression was observed *vs* negative control siRNA (Figure 6B). In contrast, the actin expression was not affected by the Hsp90 siRNA. Heat-shock protein 90 knockdown was confirmed by immunocytofluorescence (Figure 6C). Forty-eight hours after transfection, siRNA-transfected cells were tested for pro-MMP-2 and uPA secretion in the absence or presence of EDPs for 24 h. The Hsp90 knockout by siRNA1 and siRNA2 affected the protease secretion compared with negative control siRNA-transfected cells (pro-MMP-2: -56% and -52% ; uPA: -61% and -64% , respectively) (Figure 6D). In the presence of $50 \mu\text{g ml}^{-1}$ Kel, pro-MMP-2 and uPA amount still

Figure 5. Hsp90 interacts with MMP-2 and uPA. Immunoprecipitation of extracellular Hsp90 from EDP-treated HT-1080 cells' conditioned media and bound MMP-2 and uPA analysis by western blotting. Output 100% represent the unbound protein after Hsp90 immunoprecipitation.

Figure 6. Effect of Hsp90 knockdown on the EDP-regulated pro-MMP-2 and uPA secretion by HT-1080 cells. **(A)** Real-time PCR analysis of Hsp90 α transcript 2 mRNA relative expression 48 h after treatment with Hsp90 siRNA vs negative control siRNA-treated cells (–). Results (mean $\pm$ s.e.m.; $n = 3$) were expressed as the ratio of Hsp90 α transcript 1 mRNA to EEF1a1 mRNA. **(B)** Western blotting analysis and quantification of intracellular Hsp90 using a rabbit anti-Hsp90 monoclonal antibody and probing with anti-actin 72 h after treatment with Hsp90 siRNA vs negative control siRNA-treated cells (–) as described in Materials and Methods section. Results (mean $\pm$ s.e.m.) were expressed as the percentage of negative control siRNA-treated cells (EDP-untreated cells). **(C)** Immunolocalisation of Hsp90 72 h after treatment with siRNA to Hsp90 mRNA vs negative control siRNA-treated cells (–). Cells were cultured on glass slides, fixed with paraformaldehyde and labelled with an anti-Hsp90 antibody (green). Scale bar: 20 μ m. **(D)** Gelatin zymography, gelatin plasminogen zymography and western blotting analysis of conditioned media in the presence (+; 50 μ g ml $^{-1}$) or in the absence (–) of EDPs 72 h after treatment with Hsp90 siRNA vs negative control siRNA-treated cells. Quantitative evaluation of protein secretions by HT-1080 cells on gelatin zymography, gelatin plasminogen zymography and by western blotting. Results (mean $\pm$ s.e.m.) were expressed as the percentage of control (negative control siRNA/EDP-untreated cells).

increased in the negative control siRNA cells (pro-MMP-2: 222%; uPA: 225%). In the siRNA1- and siRNA2-transfected cells, Kel treatments only slightly increased pro-MMP-2 and uPA secretion. These results confirm that pro-MMP-2 and uPA secretions are independent of Hsp90 expression and that the EDP stimulation of pro-MMP-2 and uPA involves Hsp90.

Hsp90 protect secreted pro-MMP-2 and uPA from degradation.

To check pro-MMP-2 and uPA stability in the conditioned media, HT-1080 cells were treated with or without Kel (50 μ g ml $^{-1}$) for 24 h. Collected conditioned media were incubated for 6, 24 and 48 h at +37 $^{\circ}$ C and analysed by gelatin zymography for pro-MMP-2 level and gelatin plasminogen zymography for uPA level. Pro-MMP-2 and uPA contents were decreased by 85% and 90%, respectively, in the control condition after 48 h of incubation at +37 $^{\circ}$ C and only by 26% and 30%, respectively, in the medium collected after Kel treatment. Addition of recombinant Hsp90 in the control conditioned medium (50 μ g ml $^{-1}$) prevented pro-MMP-2 and uPA decrease, as observed in the Kel-treated conditioned medium (Supplementary Figure 3).

DISCUSSION

In this study, we showed that (a) EDPs increased the secretion of Hsp90; (b) this expression involved a rapid but stable posttranscriptional mechanism; (c) this EDP-dependent Hsp90 release was essential for cancer cell motility and their invasive capacities by increasing extracellular proteases. We first provided evidence that treatment of HT-1080 cells with EDPs increased Hsp90 production; a 4.5-fold increase in Hsp90 secretion was reached at 50 μ g ml $^{-1}$ EDPs, a concentration close to those determined in physiological fluids (Fülöp *et al.*, 1990). This effect could be reproduced by the VGVAPG hexapeptide, thus involving the elastin complex receptor (S-Gal/PPCA/Neu1) in triggering Hsp90 production. We previously showed that the type VIII beta-turn conformation adopted by EDPs with GXXPG sequence was essential for inducing different MMP expression in fibroblasts (Brassart *et al.*, 2001) and HT-1080 cells (Huet *et al.*, 2002). The existence of lactose-insensitive VGVAPG receptor on M27 carcinoma cells does not exclude the involvement of this type of EDP receptor in the Hsp90 secretion (Blood and Zetter, 1993).

In accordance with the stimulation of cell invasion, we showed that EDPs trigger at the same time the release of Hsp90, MMP-2 and uPA. Immunoprecipitation experiments suggested that these three extracellular proteins and the active form of pro-MMP-2 and MMP-2 were associated. This metzincin protease has largely been shown to be overexpressed in numerous cancers (Chang and Werb, 2001) and its expression by tumour cells themselves or by stromal cells leads to high invasive abilities (Polette *et al.*, 2004). Urokinase plasminogen activator is also involved in tumour invasion by regulating plasminogen activation, leading to ECM degradation and to MMP activation (Sidenius and Blasi, 2003). Increased release of these two proteases by tumour cells could be implicated in the increased invasive capacities of invasive tumour cells treated with EDPs. The EDP-dependent Hsp90 secretion by cancer cells, combined with the protease release, could explain the exacerbation of the cancer cells' invasive power in the presence of EDPs. The crucial role of extracellular Hsp90 on tumour metastasis and tumour angiogenesis has been demonstrated by the fact that rHsp90 promotes angiogenesis in an MMP-2-dependent manner, whereas Hsp90-blocking antibody suppresses it (Eustace *et al.*, 2004; Song *et al.*, 2010; Stellas *et al.*, 2010). These previous studies have shown that extracellular Hsp90 interacts with pro-MMP-2, participating in the activation process and preventing the inactivation of MMP-2. They also showed that only Hsp90 α isoform is present at the cell surface and in the conditioned media of HT-1080 fibrosarcoma cells.

Our studies are significant for several reasons. First, we confirm that extracellular Hsp90 regulates the presence of MMP-2 and demonstrate for the first time that it also regulates the presence of uPA in the pericellular environment. Both proteases interact with the extracellular Hsp90 α and the inhibition of Hsp90 by specific inhibitors, and antibody- or siRNA-mediated gene silencing inhibits the MMP-2 and uPA accumulation in the conditioned media. Second, for the first time, we show that the expression and the secretion of Hsp90 α are controlled by the interaction of EDPs with cell surface receptor. The existence of extracellular Hsp90 α has long been observed and its secretion is considered to use an unconventional way because of the lack of N-terminal signal peptide (Ullrich *et al.*, 1986; Cheng *et al.*, 2008). However, the regulatory mechanism of Hsp90 α secretion is still poorly understood. Some studies relate the fact that Hsp90 α secretion was enhanced under stress conditions, such as hypoxia and oxidative stress (Liao *et al.*, 2000; Clayton *et al.*, 2005; Li *et al.*, 2007). The question then arises of how those different stimuli lead to Hsp90 α secretion.

Among the proteases secreted by cancer cells following EDP treatment, MMP-2 is also an efficient elastase (Senior *et al.*, 1991). In addition to the fact that binding of pro-MMP-2 to elastin modulates its proteolytic activation (Emonard and Hornebeck, 1997), the further fragmentation of elastin matrix owing to the EDP-induced MMP-2 secretion can lead to an increased production of EDPs, resulting in a vicious circle where more EDPs promote more invasion and in turn generating more EDPs. Breaking this exacerbation mechanism by blocking EDP effects with elastin receptor antagonists could be beneficial in these circumstances.

The increased Hsp90 and protease release/accumulation was not related to a transcriptional effect as mRNA encoding Hsp90 α , MMP-2 and uPA were not modified. Tumour microvesicles have been linked to Hsp90 secretion (Hegmans *et al.*, 2004), and tumour invasion via release of MMP-2 and uPA (Ginestra *et al.*, 1997; Angelucci *et al.*, 2000; Dolo *et al.*, 2005; Dashevsky *et al.*, 2009). Thus, the lack of transcriptional effect, in combination with the very quick appearance of the effects of EDPs on Hsp90 protein synthesis (15 min of treatment) evokes a post-transcriptional mechanism stimulated by EDPs. A release of Hsp90 and proteases by microvesicles followed by an extracellular Hsp90 stabilisation and activation of proteases may be suggested.

In summary, our study pinpoints, for the first time, EDPs' protumoural key role by inducing Hsp90 secretion, which results in stabilisation and activation of proteases, and finally in tumour dissemination. The EDP-dependent Hsp90 secretion reinforces the fact that initial elastolysis by serine elastases from inflammatory cells or several members of the MMP family in elastin-rich tissues such as the lung, skin and breast must be considered as a main catalytic event in tumour progression.

ACKNOWLEDGEMENTS

This work was supported by grants from the Centre National de la Recherche Scientifique (UMR 7369), the University of Reims Champagne-Ardenne, the Region Champagne-Ardenne, the Délégation régionale à la Recherche et à la Technologie and the Ligue Nationale contre le Cancer. We thank Dr Christine Terryn (Plateforme IBSA 'Imagerie Cellulaire et Tissulaire') and Dr Marie-Pierre Courageot for their skilful technical assistance.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- Angelucci A, D'Ascenzo S, Festuccia C, Gravina GL, Bologna M, Dolo V, Pavan A (2000) Vesicle-associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. *Clin Exp Metast* **18**: 163–170.
- Bax DV, Rodgers UR, Bilek MMM, Weiss AS (2009) Cell adhesion to tropoelastin is mediated via the C-terminal GRKRL motif and integrin α 5 β 1. *J Biol Chem* **284**: 28616–28623.
- Blood CH, Zetter BR (1993) Laminin regulates a tumor cell chemotaxis receptor through the laminin-binding integrin subunit α 6. *Cancer Res* **53**: 2661–2666.
- Brassart B, Fuchs P, Huet E, Alix AJ, Wallach J, Tamburro AM, Delacoux F, Haye B, Emonard H, Hornebeck W, Debelle L (2001) Conformational dependence of collagenase (matrix metalloproteinase-1) up-regulation by elastin peptides in cultured fibroblasts. *J Biol Chem* **276**: 5222–5227.
- Brassart B, Randoux A, Hornebeck W, Emonard H (1998) Regulation of matrix metalloproteinase-2 (gelatinase A, MMP-2), membrane-type matrix metalloproteinase-1 (MT1-MMP) and tissue inhibitor of metalloproteinases-2 (TIMP-2) expression by elastin-derived peptides in human HT-1080 fibrosarcoma cell line. *Clin Exp Metast* **16**: 489–500.
- Chang C, Werb Z (2001) The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. *Trends Cell Biol* **11**: S37–S43.
- Chen B, Piel WH, Gui L, Bruford E, Monteiro A (2005) The HSP90 family of genes in the human genome: insights into their divergence and evolution. *Genomics* **86**: 627–637.
- Cheng CF, Fan J, Fedesco M, Guan S, Li Y, Bandyopadhyay B, Bright AM, Yerushalmi D, Liang M, Chen M, Han YP, Woodley DT, Li W (2008) Transforming growth factor α (TGF α)-stimulated secretion of HSP90 α : using the receptor LRP-1/CD91 to promote human skin cell migration against a TGF β -rich environment during wound healing. *Mol Cell Biol* **28**: 3344–3358.
- Clayton A, Turkes A, Mason MD, Tabi Z (2005) Induction of heat shock proteins in B-cell exosomes. *J Cell Sci* **118**: 3631–3638.
- Dashevsky O, Varon D, Brill A (2009) Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. *Int J Cancer* **124**: 1773–1777.
- Dolo V, D'Ascenzo S, Giusti I, Millimaggi D, Tarabozetti G, Pavan A (2005) Shedding of membrane vesicles by tumor and endothelial cells. *Ital J Anat Embryol* **110**: 127–133.
- Emonard H, Hornebeck W (1997) Binding of 92 kDa and 72 kDa progelatinases to insoluble elastin modulates their proteolytic activation. *Biol Chem* **378**: 265–271.

- Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. *Nat Cell Biol* **6**: 507–514.
- Fülöp T, Wei SM, Robert L, Jacob MP (1990) Determination of elastin peptides in normal and arteriosclerotic human sera by ELISA. *Clin Physiol Biochem* **8**: 273–282.
- Ginestra A, Monea S, Seghezzi G, Dolo V, Nagase H, Mignatti P, Vittorelli ML (1997) Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. *J Biol Chem* **272**: 17216–17222.
- Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, Kleinman HK (1989) Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures *in vitro*. *Cell* **58**: 933–943.
- Grenert JP, Johnson BD, Toft DO (1999) The importance of ATP binding and hydrolysis by hsp90 in formation and function of protein heterocomplexes. *J Biol Chem* **274**: 17525–17533.
- Hance KA, Tataria M, Ziporin SJ, Lee JK, Thompson RW (2002) Monocyte chemotactic activity in human abdominal aortic aneurysms: role of elastin degradation peptides and the 67-kD cell surface elastin receptor. *J Vasc Surg* **35**: 254–261.
- Hegmans JPJJ, Bard MPL, Hemmes A, Luijckx TM, Kleijmeer MJ, Prins JB, Zitvogel L, Burgers SA, Hoogsteden HC, Lambrecht BN (2004) Proteomic analysis of exosomes secreted by human mesothelioma cells. *Am J Pathol* **164**: 1807–1815.
- Hinek A, Boyle J, Rabinovitch M (1992) Vascular smooth muscle cell detachment from elastin and migration through elastic laminae is promoted by chondroitin sulfate-induced 'shedding' of the 67-kDa cell surface elastin binding protein. *Exp Cell Res* **203**: 344–353.
- Huet E, Brassart B, Cauchard JH, Debelle L, Birembaut P, Wallach J, Emonard H, Polette M, Hornebeck W (2002) Cumulative influence of elastin peptides and plasminogen on matrix metalloproteinase activation and type I collagen invasion by HT-1080 fibrosarcoma cells. *Clin Exp Metast* **19**: 107–117.
- Huet E, Brassart B, Wallach J, Debelle L, Haye B, Emonard H, Hornebeck W (2001) Effect of elastin peptides on the production of matrix metalloproteinase 2 by human skin fibroblasts in culture. *J Soc Biol* **195**: 165–172.
- Jacob M, Hornebeck W (1985) Isolation and characterization of insoluble and kappa-elastins. *Front Matrix Biol* **10**: 92–129.
- Kamoun A, Landeau JM, Godeau G, Wallach J, Duchesnay A, Pellat B, Hornebeck W (1995) Growth stimulation of human skin fibroblasts by elastin-derived peptides. *Cell Adhes Commun* **3**: 273–281.
- Li W, Li Y, Guan S, Fan J, Cheng CF, Bright AM, Chinn C, Chen M, Woodley DT (2007) Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing. *Eur Mol Biol Organ J* **26**: 1221–1233.
- Liao DF, Jin ZG, Baas AS, Daum G, Gygi SP, Aebersold R, Berk BC (2000) Purification and identification of secreted oxidative stress-induced factors from vascular smooth muscle cells. *J Biol Chem* **275**: 189–196.
- Maeda I, Mizoiri N, Briones MPP, Okamoto K (2007) Induction of macrophage migration through lactose-insensitive receptor by elastin-derived nonapeptides and their analog. *J Pept Sci* **13**: 263–268.
- Nackman GB, Karkowski FJ, Halpern VJ, Gaetz HP, Tilson MD (1997) Elastin degradation products induce adventitial angiogenesis in the Anidjar/Dobrin rat aneurysm model. *Surgery* **122**: 39–44.
- Ntai C, Labrousse AL, Debret R, Birembaut P, Bellon G, Antonicelli F, Hornebeck W, Bernard P (2004) Elastin-derived peptides upregulate matrix metalloproteinase-2-mediated melanoma cell invasion through elastin-binding protein. *J Invest Dermatol* **122**: 256–265.
- Polette M, Nawrocki-Raby B, Gilles C, Clavel C, Birembaut P (2004) Tumour invasion and matrix metalloproteinases. *Crit Rev Oncol* **49**: 179–186.
- Robert L (1996) Aging of the vascular wall and atherogenesis: role of the elastin–laminin receptor. *Atherosclerosis* **123**: 169–179.
- Robinet A, Fahem A, Cauchard JH, Huet E, Vincent L, Lorimier S, Antonicelli F, Soria C, Crepin M, Hornebeck W, Bellon G (2005) Elastin-derived peptides enhance angiogenesis by promoting endothelial cell migration and tubulogenesis through upregulation of MT1-MMP. *J Cell Sci* **118**: 343–356.
- Rucker RB, Dubick MA (1984) Elastin metabolism and chemistry: potential roles in lung development and structure. *Environ Health Perspect* **55**: 179–191.
- Samouillan V, Lamure A, Maurel E, Lacabanne C, Hornebeck W (2001) Alterations in the chain dynamics of insoluble elastin upon proteolysis by serine elastases. *Biopolymers* **58**: 175–185.
- Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG (1991) Human 92- and 72-kilodalton type IV collagenases are elastases. *J Biol Chem* **266**: 7870–7875.
- Senior RM, Griffin GL, Mecham RP (1980) Chemotactic activity of elastin-derived peptides. *J Clin Invest* **66**: 859–862.
- Sidenius N, Blasi F (2003) The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. *Cancer Metast Rev* **22**: 205–222.
- Sims JD, McCready J, Jay DG (2011) Extracellular heat shock protein (Hsp)70 and Hsp90α assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. *PLoS One* **6**: 12.
- Song X, Wang X, Zhuo W, Shi H, Feng D, Sun Y, Liang Y, Fu Y, Zhou D, Luo Y (2010) The regulatory mechanism of extracellular Hsp90alpha on matrix metalloproteinase-2 processing and tumor angiogenesis. *J Biol Chem* **285**: 40039–40049.
- Starkey JR (1990) Cell–matrix interactions during tumor invasion. *Cancer Metast Rev* **9**: 113–123.
- Stellas D, El Hamidieh A, Patsavoudi E (2010) Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. *BMC Cell Biol* **11**: 51.
- Timar J, Lapis K, Fulop T, Varga ZS, Tixier JM, Robert L, Hornebeck W (1991) Interaction between elastin and tumor cell lines with different metastatic potential; *in vitro* and *in vivo* studies. *J Cancer Res Clin Oncol* **117**: 232–238.
- Toupance S, Brassart B, Rabenoelina F, Ghoneim C, Vallar L, Polette M, Debelle L, Birembaut P (2012) Elastin-derived peptides increase invasive capacities of lung cancer cells by post-transcriptional regulation of MMP-2 and uPA. *Clin Exp Metast* **29**: 511–522.
- Tsutsumi S, Neckers L (2007) Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis. *Cancer Sci* **98**: 1536–1539.
- Ullrich SJ, Robinson EA, Appella E (1986) Characterization of a chemically homogeneous tumor antigen from a methylcholanthrene-induced sarcoma. *Method A* **23**: 545–555.
- Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. *Circ Res* **92**: 827–839.
- Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang Y, Tong M, Chang G, Luo Y (2009) The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. *Proc Natl Acad Sci USA* **106**: 21288–21293.
- Werb Z, Banda MJ, McKerrow JH, Sandhaus RA (1982) Elastases and elastin degradation. *J Invest Dermatol* **79**: 154s–159s.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (<http://www.nature.com/bjc>)